These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 16696815)

  • 1. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
    Gómez-Domínguez E; Gisbert JP; Moreno-Monteagudo JA; García-Buey L; Moreno-Otero R
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1643-7. PubMed ID: 16696815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
    Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
    Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
    Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
    J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
    Samy W; Hassanian MA
    Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
    Bauersachs J; Störk S; Kung M; Waller C; Fidler F; Hoyer C; Frantz S; Weidemann F; Ertl G; Angermann CE
    Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
    Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J
    Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study.
    Panichi V; Manca-Rizza G; Paoletti S; Taccola D; Consani C; Sbragia G; Mantuano E; Marchetti V; Carpi A; Barsotti G
    Biomed Pharmacother; 2006 Jun; 60(5):249-52. PubMed ID: 16740374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.